270 related articles for article (PubMed ID: 29324722)
1. Evaluation of a New Survivin ELISA and UBC
Gleichenhagen J; Arndt C; Casjens S; Meinig C; Gerullis H; Raiko I; Brüning T; Ecke T; Johnen G
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29324722
[TBL] [Abstract][Full Text] [Related]
2. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
3. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
4. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.
Shariat SF; Casella R; Khoddami SM; Hernandez G; Sulser T; Gasser TC; Lerner SP
J Urol; 2004 Feb; 171(2 Pt 1):626-30. PubMed ID: 14713774
[TBL] [Abstract][Full Text] [Related]
5. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
6. Diagnostic role of survivin in urinary bladder cancer.
Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
[TBL] [Abstract][Full Text] [Related]
7. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
[TBL] [Abstract][Full Text] [Related]
8. Detection of survivin expression in bladder cancer and renal cell carcinoma using specific monoclonal antibodies.
Chen D; Xu J; Zhang Q
Oncol Rep; 2018 Jun; 39(6):2817-2828. PubMed ID: 29658613
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.
Ritter R; Hennenlotter J; Kühs U; Hofmann U; Aufderklamm S; Blutbacher P; Deja A; Hohneder A; Gerber V; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2014 Apr; 32(3):337-44. PubMed ID: 24332643
[TBL] [Abstract][Full Text] [Related]
10. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
[TBL] [Abstract][Full Text] [Related]
11. BLCA-4 and UBC combined detection for early diagnosis of bladder cancer.
Cui L; Sun MM; Zhao ZH; Yang JP; Zheng YP; He LL; Chen KS; Fan QX
J Biol Regul Homeost Agents; 2016; 30(2):485-90. PubMed ID: 27358136
[TBL] [Abstract][Full Text] [Related]
12. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review.
Ku JH; Godoy G; Amiel GE; Lerner SP
BJU Int; 2012 Sep; 110(5):630-6. PubMed ID: 22353238
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the diagnostic accuracy of UBC
Styrke J; Henriksson H; Ljungberg B; Hasan M; Silfverberg I; Einarsson R; Malmström PU; Sherif A
Scand J Urol; 2017 Aug; 51(4):293-300. PubMed ID: 28422550
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer.
Eissa S; Badr S; Barakat M; Zaghloul AS; Mohanad M
Clin Lab; 2013; 59(7-8):893-900. PubMed ID: 24133921
[TBL] [Abstract][Full Text] [Related]
15. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
16. Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.
Ecke TH; Arndt C; Stephan C; Hallmann S; Lux O; Otto T; Ruttloff J; Gerullis H
Anticancer Res; 2015 May; 35(5):2651-5. PubMed ID: 25964541
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma.
Sánchez-Carbayo M; Ciudad J; Urrutia M; Navajo JA; Orfao A
Cancer; 2001 Dec; 92(11):2811-9. PubMed ID: 11753954
[TBL] [Abstract][Full Text] [Related]
18. Value of urinary survivin as a diagnostic marker in bladder cancer.
Abd El-Hakim TF; El-Shafie MK; Abdou AG; Azmy RM; El-Naidany SS; Badr El-Din MO
Anal Quant Cytopathol Histpathol; 2014 Jun; 36(3):121-7. PubMed ID: 25141488
[TBL] [Abstract][Full Text] [Related]
19. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
Eissa S; Badr S; Elhamid SA; Helmy AS; Nour M; Esmat M
Dis Markers; 2013; 34(1):57-62. PubMed ID: 22960341
[TBL] [Abstract][Full Text] [Related]
20. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
